Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study
Autore:
Sambo, P; Amico, D; Giacomelli, R; Matucci-Cerinic, M; Salsano, F; Valentini, G; Gabrielli, A;
Indirizzi:
Univ Ancona, Ist Clin Med Gen Ematol & Immunol Clin, I-60020 Ancona, ItalyUniv Ancona Ancona Italy I-60020 l & Immunol Clin, I-60020 Ancona, Italy Univ Florence, Dipartimento Med Interna, Div Reumatol, Florence, Italy Univ Florence Florence Italy Med Interna, Div Reumatol, Florence, Italy Univ Aquila, Dipartimento Med Interna & Sanita Pubbl, I-67100 Laquila, Italy Univ Aquila Laquila Italy I-67100 & Sanita Pubbl, I-67100 Laquila, Italy Univ Naples, Dipartimento Internist Sperimentale & Clin F Magr, Naples, Italy Univ Naples Naples Italy nist Sperimentale & Clin F Magr, Naples, Italy Univ La Sapienza, Dipartimento Med Clin, Serv Immunol Clin & Allergol, Rome, Italy Univ La Sapienza Rome Italy , Serv Immunol Clin & Allergol, Rome, Italy
Titolo Testata:
JOURNAL OF RHEUMATOLOGY
fascicolo: 10, volume: 28, anno: 2001,
pagine: 2257 - 2262
SICI:
0315-162X(200110)28:10<2257:INFTOR>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL-ADHESION MOLECULE-1; CONTROLLED DOUBLE-BLIND; ENDOTHELIAL-CELLS; ORAL ILOPROST; NITRIC-OXIDE; HYDROGEN-PEROXIDE; ORGANIC NITRATES; SCLERODERMA; MULTICENTER; OXIDATION;
Keywords:
scleroderma; oxidative stress; Raynaud's phenomenon; N-acetylcysteine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Gabrielli, A Univ Ancona, Ist Clin Med Gen Ematol & Immunol Clin, Polo Didattico,Via Tronto 10, I-60020 Ancona, Italy Univ Ancona Polo Didattico,Via Tronto 10 Ancona Italy I-60020
Citazione:
P. Sambo et al., "Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study", J RHEUMATOL, 28(10), 2001, pp. 2257-2262

Abstract

Objective. To assess the efficacy and tolerability of N-acetylcysteine (NAC in patients with Raynaud's phenomenon (RP) secondary to Systemic sclerosis (scleroderma; SSc). Methods. Twenty-two patients with RP secondary to SSc were enrolled in a multicenter, open clinical trial lasting I I weeks and conducted in winter. Primary outcome measures were frequency and severity of RP attacks, and number of digital ulcers. Secondary outcome measure was improvement in digitalcold challenge test assessed by photoelectric plethysmography. Patients received a continuous 5 day intravenous infusion of NAC starting with a 2 h loading dose of 150 mg/kg subsequently adjusted to 15 mg/kg/h. Results. All 22 patients completed the 5 day infusion and 20 of them the Posttreatment followup. Both frequency and severity of RP attacks decreased significantly compared to pretreatment values. Active ulcers were significantly less numerous at all followup visits (25.18% of baseline count on Day 33 from the beginning of infusion). In the cold challenge test mean recovery time fell by 69.56%, 67.70%, 71.42%, and 71.05% on Days 12, 19, 33, and 61 from the beginning of treatment. Side effects were minor, easily controlled, and reversible. Conclusion. N-acetylcysteine appears to be safe for the treatment of RP secondary to SSc. These preliminary data warrant further controlled studies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 12:43:39